Vertex Pharmaceuticals INC / Ma Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
NASDAQ
Capital Research Global Investors has filed a Schedule 13G, reporting beneficial ownership of 8.3% of Vertex Pharmaceuticals Inc. common stock as of March 31, 2026.
NASDAQ
Vanguard Capital Management has reported beneficial ownership of 19,036,076 shares, representing 7.49% of Vertex Pharmaceuticals Inc.'s common stock as of March 31, 2026.
NASDAQ
The Vanguard Group, Inc. reports 0% beneficial ownership of Vertex Pharmaceuticals Inc. common stock following an internal realignment.
NASDAQ
SCHEDULE 13G: Capital Research Global Investors Discloses 5.7% Passive Stake in Vertex Pharmaceuticals
Capital Research Global Investors has reported a 5.7% passive beneficial ownership stake in Vertex Pharmaceuticals Inc., holding over 14.5 million shares as of March 31, 2025.
NASDAQ
Capital World Investors, a division of Capital Research and Management Company, has reported a passive beneficial ownership of 11.2% in Vertex Pharmaceuticals Inc., totaling 28,739,975 shares of common stock as of December 31, 2024.
NASDAQ
FMR LLC and its CEO, Abigail P. Johnson, have filed an amended Schedule 13G, reporting a beneficial ownership of 3.6% of Vertex Pharmaceuticals Inc.'s common stock as of December 31, 2024.